SCHEMBL212833

SCHEMBL212833

CC(=O)N(NCc1cccc(F)c1Cl)[C@@H](CCC(=O)O)COC(=O)Nc1cc(-c2ccccc2)no1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.41
SMN1; SMN2 Q16637 5/20 0.37
TP53 P04637 3/20 0.37
RORC P51449 1/20 0.36
PTGFR P43088 5/20 0.36
THRB P10828 1/20 0.34
MMP2 P08253 2/20 0.34
MMP8 P22894 2/20 0.34
MMP12 P39900 2/20 0.34
MMP3 P08254 1/20 0.33
MMP10 P09238 1/20 0.33
MMP9 P14780 1/20 0.33
MMP13 P45452 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214097 0.95 MAPT (0.38) MAPTSMN1; SMN2TP53RORCPTGFR
SCHEMBL212322 0.94 MAPT (0.40) MAPTSMN1; SMN2TP53RORCPTGFR
SCHEMBL212146 0.92 MAPT (0.42) MAPTSMN1; SMN2TP53RORCPTGFR
SCHEMBL4343014 0.90 MAPT (0.37) MAPTSMN1; SMN2TP53RORC
SCHEMBL2838804 0.88 MAPT (0.37) MAPTSMN1; SMN2TP53RORCPTGFR
SCHEMBL210624 0.88 MAPT (0.41) MAPTSMN1; SMN2TP53RORCTHRB
SCHEMBL212601 0.88 MAPT (0.37) MAPTSMN1; SMN2TP53RORCTHRB
SCHEMBL212834 0.87 MAPT (0.41) MAPTSMN1; SMN2TP53RORCPTGFR
SCHEMBL210463 0.87 MAPT (0.41) MAPTSMN1; SMN2TP53RORCTHRB
SCHEMBL211287 0.86 MAPT (0.34) MAPTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895582-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-11-25 US disclosed
US-8759374-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2014-06-24 US disclosed
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2013-02-28 US disclosed
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS QIAN XIANGPING (US) 2012-05-31 US disclosed
US-8088793-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2012-01-03 US disclosed
US-20090275537-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275537-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 MAPT 530/4885SMN1; SMN2 252/4885TP53 2206/4885
US-20120135964-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 MAPT 530/4885SMN1; SMN2 252/4885TP53 2206/4885
US-20130053348-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS MYLK, MYH2, MYH10 MAPT 530/4885SMN1; SMN2 252/4885TP53 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.